scholarly journals Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: A scoping review

2020 ◽  
Author(s):  
Johanna Thunell ◽  
Yi Chen ◽  
Geoffrey Joyce ◽  
Douglas Barthold ◽  
Paul G. Shekelle ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Scoping Review ◽  
Chronic Conditions

scholarly journals Promoting Conversations About Cognitive Decline Between Older Adults and Primary Care Providers

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 157-158
Author(s):  
Benjamin Olivari ◽  
Christopher Taylor ◽  
Nia Reed ◽  
Lisa McGuire
Keyword(s):  
Alzheimer’S Disease ◽  
Primary Care ◽  
Alzheimer's Disease ◽  
Cognitive Impairment ◽  
Cognitive Decline ◽  
Chronic Conditions ◽  
Memory Loss ◽  
Primary Care Providers ◽  
Subjective Cognitive Decline ◽  
Care Providers

Abstract Alzheimer’s disease and related dementias often begin with symptoms of mild memory loss, eventually leading to more severe cognitive impairment, functional impairment, and ultimately, death. Data from the Behavioral Risk Factor Surveillance System core questions related to chronic diseases and from the cognitive decline optional module on subjective cognitive decline (SCD) from the years 2015-2018 were aggregated across the participating 50 states, D.C., and Puerto Rico for this analysis. Among U.S. adults aged 65 years and older, only 39.8% (95%CI=37.6-42.1) of those experiencing SCD reported discussing their SCD symptoms with a healthcare provider. The prevalence of discussing SCD symptoms with a provider was higher among those with at least one chronic condition than among those with no chronic conditions. 30.7% (28.6-32.8) of those aged 65 years and older reported that their SCD led to functional limitations and 28.8% (26.5-31.2) needed assistance with day-to-day activities. For patients aged 65 years and older, Welcome to Medicare visits and Medicare Annual Wellness Visits are critically underutilized primary care access points. Primary care providers can manage chronic conditions, cognitive health, and initiate referrals for testing. Efforts to promote the use of toolkits and diagnostic codes that are available to primary care providers to initiate conversations about memory loss with patients may be utilized to improve detection, diagnosis, and planning for memory problems. Discussions may lead to earlier detection and diagnosis of cognitive impairment, such as Alzheimer’s disease, or other treatable conditions such as delirium or pressure in the brain and avoid costly hospitalizations.

scholarly journals Environmental Substances Associated with Alzheimer’s Disease—A Scoping Review

2021 ◽  
Vol 18 (22) ◽  
pp. 11839
Author(s):  
Hanna Maria Elonheimo ◽  
Helle Raun Andersen ◽  
Andromachi Katsonouri ◽  
Hanna Tolonen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Scoping Review ◽  
Cognitive Abilities ◽  
Human Biomonitoring ◽  
Chemical Exposure ◽  
Priority Substances ◽  
Environmental Chemical ◽  
Other Substances ◽  
Neurological Effects

Alzheimer’s disease (AD) is the most common form of dementia, prevalent in approximately 50–70% of the dementia cases. AD affects memory, and it is a progressive disease interfering with cognitive abilities, behaviour and functioning of the person affected. In 2015, there were 47 million people affected by dementia worldwide, and the figure was estimated to increase to 75 million in 2030 and to 132 million by 2050. In the framework of European Human Biomonitoring Initiative (HBM4EU), 18 substances or substance groups were prioritized for investigation. For each of the priority substances, a scoping document was prepared. Based on these scoping documents and complementary review of the recent literature, a scoping review of HBM4EU-priority substances which might be associated with AD was conducted. A possible association between risk of AD and pesticides was detected. For mercury (Hg), association is possible but inconsistent. Regarding cadmium (Cd) and arsenic (As), the results are inconsistent but inclined towards possible associations between the substances and the risk of disease. The evidence regarding lead (Pb) was weaker than for the other substances; however, possible associations exist. Although there is evidence of adverse neurological effects of environmental substances, more research is needed. Environmental chemical exposure and the related hazards are essential concerns for public health, and they could be preventable.

scholarly journals Drug treatment for early Alzheimer's disease

1998 ◽  
Vol 4 (3) ◽  
pp. 126-134 ◽  
Author(s):  
Roger Bullock
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Biology ◽  
Drug Treatment ◽  
21St Century ◽  
Chronic Conditions ◽  
Epidemiological Studies ◽  
Early Alzheimer’S Disease

Alzheimer's disease is likely to be one of the challenges for the early part of the 21st century. Better knowledge of the molecular biology, genetics and pathogenesis of the condition have led to a host of psychopharmacological compounds being developed which may help in its the treatment, while epidemiological studies have suggested that existing treatments for other chronic conditions may have an effect on the presentation of Alzheimer's disease.

Transitioning into the caregiver role following a diagnosis of Alzheimer’s disease or related dementia: A scoping review

2019 ◽  
Vol 96 ◽  
pp. 119-131 ◽  
Author(s):  
Kyungmi Lee ◽  
Frank Puga ◽  
Carolyn E.Z. Pickering ◽  
Sara S. Masoud ◽  
Carole L. White
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Scoping Review ◽  
Caregiver Role

scholarly journals THE RELATIONSHIP BETWEEN ALZHEIMER’S DISEASE AND ORAL HEALTH: A SCOPING REVIEW

2017 ◽  
Vol 1 (suppl_1) ◽  
pp. 398-398
Author(s):  
G. Mathur ◽  
K. Mehndiratta ◽  
T. Yasmina ◽  
N. Bhela ◽  
R.M. Mirza
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Oral Health ◽  
Scoping Review ◽  
The Relationship

Would Some Herbal Teas Play Medicating Role for Certain Diseases?

2020 ◽  
Vol 16 ◽  
Author(s):  
Tabinda Sattar
Keyword(s):  
Alzheimer’S Disease ◽  
Cardiovascular Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Human Health ◽  
Chronic Conditions ◽  
Attractive Alternative ◽  
Herbal Tea ◽  
Anti Inflammation

: Herbal Teas prepared from leaves, roots, fruits and flowers of different herbs contain many useful nutrients that may be a good replacement for medicating of certain specific diseases. These herbal teas are very rich in poly-phenols so these are very much significant for their antioxidant, anti-inflammation, anticancer, anticardiovascular, antimicrobial, antihyperglycemic, and antiobesity properties. Medical chronic conditions such as cardiovascular disease, cancer, Alzheimer’s disease, Parkinson’s disease, constipation, diabetes and bed wetting in children can be easily cured by the use of these herbal teas in regular and moderate amounts. This Review focuses on the diverse constituents of herbal tea due to which it can be an attractive alternative toward promoting human health.

P1-421: Sensory Screening in Dementia and Alzheimer's Disease: A Scoping Review

2016 ◽  
Vol 12 ◽  
pp. P596-P596 ◽  
Author(s):  
Katherine S. McGilton ◽  
Fiona Hobler ◽  
Dawn Guthrie ◽  
Jennifer Campos ◽  
Jonathan Jarry ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Scoping Review

scholarly journals Prevalence of Diagnosed Alzheimer’s Disease and Related Dementias in Medicare Advantage

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 58-59
Author(s):  
Eric Jutkowitz ◽  
Julie Bynum ◽  
Susan Mitchell ◽  
Noelle Cocoros ◽  
Oren Shapira ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Chronic Conditions ◽  
Index Date ◽  
Medicare Advantage ◽  
Medicare Beneficiaries ◽  
Icd 10 ◽  
Predominately Female ◽  
Age And Sex

Abstract A third of Medicare beneficiaries are enrolled in Medicare Advantage (MA); however, little is known about MA beneficiaries diagnosed with Alzheimer’s disease and related dementias (AD/ADRD). MA plans have incentives that may influence the type of beneficiaries who enroll/disenroll from plans and the documentation of diagnoses. We calculated the prevalence of diagnosed AD/ADRD in 2014 and 2016 in three MA plans representing ~30% of the MA market. We identified beneficiaries ≥65 years of age enrolled in the MA plans in 2014 and 2016. Among eligible beneficiaries, we identified individuals with AD/ADRD using ICD-9 (2014) and ICD-10 (2016) codes included in the Medicare Chronic Conditions Warehouse algorithms for AD/ADRD. We determined the age and sex of beneficiaries diagnosed with AD/ADRD, and whether they disenrolled from the MA plan for any reason (e.g., death, enrollment in a different MA plan, enrollment in traditional Medicare or discontinuation of a plan) within 364 days from the date they were first identified has having AD/ADRD (i.e., index date). In 2014 and 2016 the prevalence of AD/ADRD diagnoses was 5.7% and 6.5%, respectively. In 2016, AD/ADRD beneficiaries were on average 82.4 (SD=7.3) years of age, 61.8% female, and had multiple comorbidities. By 364 days post-index, 32% of beneficiaries with diagnosed AD/ADRD had disenrolled from their plan. The characteristics of 2014 beneficiaries with diagnosed AD/ADRD were similar to their 2016 counterparts. In conclusion, MA beneficiaries with AD/ADRD are predominately female, have multimorbidity, and the age-stratified prevalence of AD/ADRD diagnoses is lower than rates reported in traditional Medicare.

Sign in / Sign up

Export Citation Format

Share Document